| Filed On | Filing |
|---|---|
| 05 Nov 2026 | SCHEDULE 13G/A |
| 29 Oct 2026 | 10-Q |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance |
| 26 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
EXECUTION VERSION Credit Agreement - West Pharma (2026) (Conformed Signatures for 8-K Filing)(24019362844.2) - 10/26/2026 3:26:03 PM Deal CUSIP Number: 95530RAH2 Revolver A: 95530RAJ8 Revolver B: 95530RAL3 Term A Facility: 95530RAK5 CRED... |
| 02 Oct 2026 |
Form 4: Haugen Janet Brutschea, Director
Granted 44 Phantom Stock Unit ($16.3K) |
| 15 Sep 2026 |
Form 4: Favorite Annette F, Sr. VP & Chief HR Officer
Received 2,500 shares by exercise or conversion ($224K) · Sold 2,500 shares ($863K) · Received 2,500 shares by exercise or conversion ($224K) · 3 more |
| 10 Sep 2026 |
Form 4: Favorite Annette F, Sr. VP & Chief HR Officer
Received 8,135 shares by exercise or conversion ($694K) · Sold 8,135 shares ($2.77M) |
| 10 Sep 2026 |
Form 4: Lagarde Michel, Director
Granted 37,048 Stock Option (Right to Buy) · Granted 14,750 Rst. Stock Unit |
| 10 Sep 2026 |
Form 3: Lagarde Michel, Director
Holds 7,850 shares of Common Stock |
| 12 Aug 2026 |
Form 4: McMahon Robert W., SVP & Chief Financial Officer
Received 7,149.205 shares by exercise or conversion · Gave up 3,109.19 shares to cover exercise price or tax ($1.09M) |
| 06 Aug 2026 | SCHEDULE 13G |
| 23 Jul 2026 | 10-Q |
| 23 Jul 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Exton, PA, July 23, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the second quarter of 2026. |
| 14 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
West Pharmaceutical Services, Inc. (the "Company") and Daikyo Seiko, Ltd. ("Daikyo") have entered into an Amended and Restated Technology Exchange and Crosslicense Agreement (the “Crosslicense Agreement”) as well as two Distributorship A... |
| 01 Jul 2026 |
Form 4: Haugen Janet Brutschea, Director
Granted 46 Phantom Stock Unit ($16.5K) |
| 01 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) dated as of May 31, 2026 (the “Effective Date”) is entered by and between West Pharmaceutical Services, Inc., a Pennsylvania corporation (the “Company... |
| 20 May 2026 |
8-K/A: Material Cybersecurity Incidents
As previously disclosed in the Original Report, the Company determined on May 7, 2026 that the Company had experienced a material cybersecurity attack, in which certain data was exfiltrated by an unauthorized party and certain systems we... |
| 14 May 2026 |
Form 4: Campbell Shane Alden, SVP, Proprietary Segment
Received 769.588 shares by exercise or conversion · Gave up 219.256 shares to cover exercise price or tax ($68.4K) |
| 13 May 2026 | SD |
| 11 May 2026 |
8-K: Material Cybersecurity Incidents; Regulation FD Disclosure
West is committed to providing timely and transparent communication to all stakeholders regarding the recent cyberattack on its network systems. Following initial detection of an intrusion on May 4, 2026, West Pharmaceutical Services pro... |
Loading...